VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy

• DOI: 10.1016/j.annonc.2021.10.007
• Publication Date: 2021-11-19T12:24:13Z
• Authors: S. Lu; L. Wu; H. Jian; Y. Cheng; Q. Wang; J. Fang; Z. Wang; Y. Hu; M. Sun; L. Han; L. Miao; C. Ding; J. Cui; B. Li; X. Li; K. Wang; S. Cang; Y. Pan; F. Ye; A. Liu
• Keywords: Pemetrexed; Interim analysis; Clinical endpoint; Progression-free survival